ArticleHuman vaccines & immunotherapeutics2026
Estimating the potential public health and economic impact of vaccination timing: A modeling study of COVID-19 vaccination in the United Kingdom.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the public health and economic impact of timely protection against COVID-19 infection with an adapted vaccine in the United Kingdom. A static decision-tree model was used to estimate the impact of timely protection with an autumn dose and a spring dose and assess how delays in the start of the vaccination program affect the impact. The model examined a hypothetical year based on the average age-stratified incidence and severity reported in public health surveillance data for the 2022/2023 and the 2023/2024 seasons. Other age-stratified parameters vaccine coverage, cost, and vaccine effectiveness parameters were informed by literature. Timely protection with the autumn dose for those aged ≥75 y and the high-risk population aged 18-74 was estimated to avert 1.0 million cases, 15,642 hospitalization, 3,897 deaths, 82,977 post-COVID condition cases, £179 million in direct medical costs, and £195 million in productivity losses. Timely protection with the spring dose for those aged ≥75 y and the high-risk population aged 18-74 was estimated to avert 98,446 cases, 1,477 hospitalization, 279 deaths, 8,357 post-COVID condition cases, £6 million in direct medical costs, and £14 million in productivity losses. Delays in the start of the vaccination program substantially reduced the estimated public health and economic impact of vaccination for both the autumn and spring doses. Adapted vaccines for COVID-19 remain an important public health tool for reducing the health and economic burden. However, delays in the start of vaccination campaigns may erode the potential impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.